Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2022-09-14 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 204.9KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from InhaleRx Limited regarding a trading halt requested pending the release of an announcement related to a proposed capital raising. It references ASX Listing Rule 17.1 and is dated 15 September 2022. The content is brief (1820 characters) and does not contain any financial data or detailed report information. It is an announcement about a trading halt due to an upcoming capital raising announcement, not the capital raising update itself. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities, specifically a capital raising event.
2022-09-14 English
Half Yearly Report and Accounts 18 pages 1.6MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'InhaleRx Limited Appendix 4D Half-year report' and references the half-year ended 30 June 2022, indicating it is a report for a period shorter than a full fiscal year. It contains detailed financial statements including profit or loss, financial position, cash flows, notes, and an auditor's review report. The presence of comprehensive financial data and analysis for the half-year period confirms it is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. H1 2022
2022-08-30 English
Quarterly Appendix 4C Cash Flow Report 5 pages 325.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities. It includes specific quarterly financial data, reconciliation of cash and cash equivalents, payments to related parties, financing facilities, and estimated cash available for future operating activities. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. The presence of detailed financial statements and analysis for a quarter matches the definition of an Interim / Quarterly Report (IR). Q4 2022
2022-07-27 English
Quarterly Activities Report 5 pages 706.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled as an ASX Announcement and provides a quarterly activities report, cash flow report, and operations update for the quarter ended 30 June 2022. It includes detailed operational highlights, clinical development updates, regulatory progress, licensing information, payments to directors, and use of funds during the quarter. The content is comprehensive and includes substantive financial data such as cash reserves, net cash used in operating activities, and breakdown of expenses. The document is 8865 characters long, which is substantial and contains actual financial and operational data rather than just an announcement or a link to a report. This matches the characteristics of an Interim / Quarterly Report (IR) rather than a brief announcement or a full annual report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2022
2022-07-27 English
Ceasing to be a substantial holder 2 pages 748.8KB
Regulatory Filings
2022-07-03 English
Notification of cessation of securities - IRX 4 pages 24.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options (unquoted equity securities) for Inhalerx Limited. It provides specifics about the securities that have ceased, the reason for cessation (expiry of option), and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an announcement related to capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation of securities.
2022-06-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.